Indian J Pharm Close
 

Figure 5: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)-mediated intracellular accumulation of rhodamine 123. Cells were pretreated with or without 1.0 μM of DMAG (verapamil as a positive control) for 1 h, then incubated with 5 mg/L of Hoechst 33342 for 10 min and 5 mg/L of Rh123 for another 1 h in the dark, (a) Fluorescence intensity of rhodamine 123 in the presence or absence of DMAG in K562 cells. (b) Fluorescence intensity of rhodamine 123 in the presence or absence of DMAG in K562/DOX cells.﹡Represents P < 0.05. (c) Image of fluorescence intensity of rhodamine 123. (c-1) K562 cells untreated. (c-2) K562 cells treated with 1.0 μM of 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG). (c-3) K562 cells treated with 1.0 μM of verapamil. (c-4) K562/DOX cells untreated. (c-5) K562/DOX cells treated with 1.0 μM of DMAG. (c-6) K562/ DOX cells treated with 1.0 μM of verapamil.×40

Figure 5: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)-mediated intracellular accumulation of rhodamine 123. Cells were pretreated with or without 1.0 μM of DMAG (verapamil as a positive control) for 1 h, then incubated with 5 mg/L of Hoechst 33342 for 10 min and 5 mg/L of Rh123 for another 1 h in the dark, (a) Fluorescence intensity of rhodamine 123 in the presence or absence of DMAG in K562 cells. (b) Fluorescence intensity of rhodamine 123 in the presence or absence of DMAG in K562/DOX cells.﹡Represents <i>P</i> < 0.05. (c) Image of fluorescence intensity of rhodamine 123. (c-1) K562 cells untreated. (c-2) K562 cells treated with 1.0 μM of 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG). (c-3) K562 cells treated with 1.0 μM of verapamil. (c-4) K562/DOX cells untreated. (c-5) K562/DOX cells treated with 1.0 μM of DMAG. (c-6) K562/ DOX cells treated with 1.0 μM of verapamil.×40